TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.
Brief Summary: Over time, patients with fibrosing or interstitial lung disease (ILD) can develop high lung blood pressures (pulmonary hypertension), and this is associated with poorer prognosis and survival. It is thought that development of PH contributes to the deterioration and death of patients with ILD. Endothelin-1 (ET1) is a substance contributing to the development of both PH and ILD. Bosentan is a drug blocking the action of ET-1 by binding to its receptors. Bosentan clearly benefits patients with PH of unknown cause, or related to other diseases (such as heart conditions, or HIV) both alone and in combination with other treatments. In patients with fibrosing lung disease and PH, there have been no controlled treatment studies. Clearly it is important to evaluate the effectiveness of bosentan in these patients.

This study aims to determine the ability of bosentan to reduce high blood pressure in the lungs (pulmonary hypertension) in patients with scarring (fibrosing) lung disease. It is a placebo-controlled double blinded study for 16 weeks (and it is proposed to follow patients in a 16 week open-label phase with bosentan therapy).


Options:
A: Arm Label: STI571; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: All Patients; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Intervention Type: DRUG; Name: Imatinib mesylate; Assigned to Arm(s): All Patients, STI571 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A
D: Arm Label: Part 1; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 2; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 3; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Intervention Type: DRUG; Name: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose; Assigned to Arm(s): Part 1, Part 2, Part 3 | Intervention Type: DRUG; Name: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently); Assigned to Arm(s): Part 1, Part 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants: The Canadian Oxygen Trial (COT)
Brief Summary: Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pulse oximetry (SpO2)of 85-89% compared with 91-95%, from the day of birth until the baby's first discharge home, increase the probability of survival without severe neurosensory disability to a corrected age of 18 months?


Options:
A: Arm Label: Automatic Oxygen Control; Type: EXPERIMENTAL; Interventions: Device: Automatic Oxygen control | Arm Label: Manual oxygen control; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Oxygen Control | Intervention Type: DEVICE; Name: Automatic Oxygen control; Assigned to Arm(s): Automatic Oxygen Control | Intervention Type: OTHER; Name: Manual Oxygen Control; Assigned to Arm(s): Manual oxygen control
B: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
C: Arm Label: Manual oxygen control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Closed-loop automated oxygen control; Type: OTHER; Interventions: Device: Closed-loop automated oxygen control (Oxygenie, SLE 6000) | Intervention Type: DEVICE; Name: Closed-loop automated oxygen control (Oxygenie, SLE 6000); Assigned to Arm(s): Closed-loop automated oxygen control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Titration of oxygen therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Titration of oxygen therapy | Intervention Type: OTHER; Name: Titration of oxygen therapy; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine co-administered with GlaxoSmithKline Biologicals' HPV vaccine GSK580299 in healthy female subjects.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F
B: Arm Label: Cervarix™ & Engerix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™), Biological: Engerix™ | Arm Label: Engerix™ Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix™ | Intervention Type: BIOLOGICAL; Name: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™); Assigned to Arm(s): Cervarix™ & Engerix™ Group | Intervention Type: BIOLOGICAL; Name: Engerix™; Assigned to Arm(s): Cervarix™ & Engerix™ Group, Engerix™ Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Procedure: Liquid-based cytology (LBC) sampling, Procedure: Blood sampling | Arm Label: Aimmugen Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Liquid-based cytology (LBC) sampling | Intervention Type: PROCEDURE; Name: Liquid-based cytology (LBC) sampling; Assigned to Arm(s): Aimmugen Group, Cervarix Group | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
D: Arm Label: Patients; Type: OTHER; Interventions: Other: Human papilloma virus vaccine (cervarix) | Intervention Type: OTHER; Name: Human papilloma virus vaccine (cervarix); Assigned to Arm(s): Patients

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
Brief Summary: This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): 2
B: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin, Drug: placebo | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Met Mono; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: placebo | Arm Label: Met + Glim; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met + Glim, Met Mono | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Met + Glim | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met Mono | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Met + Glim, Met Mono | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met
C: Intervention Type: DRUG; Name: Albiglutide (GSK716155) or exenatide; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: exenatide once weekly, Drug: placebo tablet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: placebo once weekly | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone, Drug: placebo once weekly | Intervention Type: DRUG; Name: exenatide once weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo once weekly; Assigned to Arm(s): 2, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Brief Summary: This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: Ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Brief Summary: Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.


Options:
A: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matching placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): matching placebo
D: Arm Label: mifepristone 300 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: mifepristone matched placebo | Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 600 mg | Arm Label: mifepristone 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 1200 mg | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone 300 mg | Intervention Type: DRUG; Name: mifepristone matched placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: mifepristone 600 mg; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: mifepristone 1200 mg; Assigned to Arm(s): mifepristone 1200 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/Phase III Study of the Effect of Combined High-frequency Oscillation and Tracheal Gas Insufflation on the Survival to Hospital Discharge of Patients With Severe Acute Respiratory Distress Syndrome
Brief Summary: The investigators have recently demonstrated the beneficial effects of combined high-frequency oscillation (HFO) and tracheal gas insufflation (TGI) on the respiratory physiology \[1,2\] of patients with severe acute respiratory distress syndrome (ARDS) (NCT00416260). Preliminary short-term survival results were also encouraging. Consequently, in the present clinical trial, the investigators intend to increase the size of the studied population, in order to evaluate the effect of HFO-TGI on survival with adequate statistical power. Furthermore, the investigators intend to elucidate the mechanism of the HFO-TGI-related physiological benefit.


Options:
A: Arm Label: Conventional Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung Protective Ventilation | Arm Label: High Frequency Oscillation; Type: EXPERIMENTAL; Interventions: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator | Intervention Type: DEVICE; Name: SensorMedics 3100B High Frequency Oscillatory Ventilator; Assigned to Arm(s): High Frequency Oscillation | Intervention Type: PROCEDURE; Name: Lung Protective Ventilation; Assigned to Arm(s): Conventional Ventilation
B: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: High-frequency Oscillation and Tracheal Gas Insufflation | Intervention Type: OTHER; Name: High-frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): 1
D: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes Assessment in Chronic GVHD
Brief Summary: The purpose of this study is to see if recent guidelines proposed by the National Institutes of Health for the diagnosis, staging, and response assessment of people with chronic GVHD can improve our understanding of this complication. We will accomplish our goals by studying a large number of people with chronic GVHD over several years using information collected from health care providers, patients, laboratory studies and diagnostic tests. Several transplant centers in the United States are collaborating on this project.


Options:
A: Arm Label: ECP Methoxsalen + Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: ECP Methoxsalen, Drug: Standard of Care | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: ECP Methoxsalen; Assigned to Arm(s): ECP Methoxsalen + Standard of Care | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): ECP Methoxsalen + Standard of Care, Standard of Care
B: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes Assessment in Chronic GVHD
Brief Summary: The purpose of this study is to see if recent guidelines proposed by the National Institutes of Health for the diagnosis, staging, and response assessment of people with chronic GVHD can improve our understanding of this complication. We will accomplish our goals by studying a large number of people with chronic GVHD over several years using information collected from health care providers, patients, laboratory studies and diagnostic tests. Several transplant centers in the United States are collaborating on this project.


Options:
A: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A
B: N/A
C: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain
Brief Summary: The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies.


Options:
A: Intervention Type: DRUG; Name: oxycodone fentanyl; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: oxycodone, Drug: pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone, Drug: pregabalin | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): A, B
C: Arm Label: Genotype Arm; Type: EXPERIMENTAL; Interventions: Genetic: CYP2D6, Behavioral: Brief Pain Inventory-Short Form (BPI-SF), Behavioral: M.D. Anderson Symptom Inventory (MDASI), Genetic: OPRM1 | Arm Label: Traditional Arm; Type: ACTIVE_COMPARATOR; Interventions: Genetic: CYP2D6, Behavioral: Brief Pain Inventory-Short Form (BPI-SF), Behavioral: M.D. Anderson Symptom Inventory (MDASI), Genetic: OPRM1 | Intervention Type: GENETIC; Name: CYP2D6; Assigned to Arm(s): Genotype Arm, Traditional Arm | Intervention Type: BEHAVIORAL; Name: Brief Pain Inventory-Short Form (BPI-SF); Assigned to Arm(s): Genotype Arm, Traditional Arm | Intervention Type: BEHAVIORAL; Name: M.D. Anderson Symptom Inventory (MDASI); Assigned to Arm(s): Genotype Arm, Traditional Arm | Intervention Type: GENETIC; Name: OPRM1; Assigned to Arm(s): Genotype Arm, Traditional Arm
D: Arm Label: Oxycodone Hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone Hydrochloride | Arm Label: Morphine Sulphate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulphate | Intervention Type: DRUG; Name: Oxycodone Hydrochloride; Assigned to Arm(s): Oxycodone Hydrochloride | Intervention Type: DRUG; Name: Morphine Sulphate; Assigned to Arm(s): Morphine Sulphate

Answer: B